T2 Biosystems (TTOO) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
T2 Biosystems Reports 2014 Third Quarter Highlights and Financial Results
November 4, 2014 4:00 PM ESTLEXINGTON, Mass., Nov. 4, 2014 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq: TTOO) today reported operating highlights and financial results for the third quarter ended September 30, 2014. Highlights of the quarter included:
In September, the Company received authorization from the U.S. Food and Drug Administration (FDA) to market its first two products, the T2Candida® Panel and the T2Dx® Instrument for the detection of Candida species in whole blood specimens from patients with symptoms of, or... More